Business, energy, technology, markets and global industry news from Business News Today

Otsuka Holdings Co.

PharmaDeviceNews Otsuka Holdings Co.
Otsuka’s FDA approval of SIMTRIYO, or centanafadine, introduces a first-in-class ADHD treatment for adults and children aged six and older, although DEA scheduling, safety monitoring and payer access will shape its commercial adoption. Representative image.
Pharma & Biotech

Otsuka’s SIMTRIYO has FDA approval, but two hurdles will decide whether it can disrupt ADHD care

Otsuka’s SIMTRIYO wins FDA approval for ADHD, but DEA scheduling, boxed warnings and payer access will shape its commercial uptake.

Read More
Representative image: Otsuka’s centanafadine Phase 3b results highlight the investigational ADHD treatment’s potential in adults with comorbid anxiety ahead of the FDA decision.
Pharma & Biotech

Could centanafadine reshape nonstimulant ADHD treatment after Otsuka’s Phase 3b success?

Discover how Otsuka’s centanafadine Phase 3b ADHD data could shape FDA review and the nonstimulant treatment market. Read more.

Read More